Eastwood Bio Medical Canada Stock Performance
| EBM Stock | CAD 0.40 0.05 11.11% |
The firm shows a Beta (market volatility) of 3.7, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eastwood Bio will likely underperform. At this point, Eastwood Bio Medical has a negative expected return of -0.11%. Please make sure to confirm Eastwood Bio's skewness, as well as the relationship between the day median price and relative strength index , to decide if Eastwood Bio Medical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eastwood Bio Medical Canada has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 39.8 K |
Eastwood |
Eastwood Bio Relative Risk vs. Return Landscape
If you would invest 75.00 in Eastwood Bio Medical Canada on November 2, 2024 and sell it today you would lose (35.00) from holding Eastwood Bio Medical Canada or give up 46.67% of portfolio value over 90 days. Eastwood Bio Medical Canada is currently producing negative expected returns and takes up 14.6407% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Eastwood, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Eastwood Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eastwood Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eastwood Bio Medical Canada, and traders can use it to determine the average amount a Eastwood Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0075
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EBM |
Estimated Market Risk
| 14.64 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eastwood Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eastwood Bio by adding Eastwood Bio to a well-diversified portfolio.
Eastwood Bio Fundamentals Growth
Eastwood Stock prices reflect investors' perceptions of the future prospects and financial health of Eastwood Bio, and Eastwood Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eastwood Stock performance.
| Return On Equity | -7.47 | |||
| Return On Asset | -0.64 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.51) % | |||
| Current Valuation | 27.61 M | |||
| Shares Outstanding | 68.89 M | |||
| Price To Earning | (11.43) X | |||
| Price To Book | 2,943 X | |||
| Price To Sales | 42.16 X | |||
| Revenue | 867.94 K | |||
| EBITDA | (398.19 K) | |||
| Cash And Equivalents | 708.26 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 23.08 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (16.89 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 489.14 K | |||
| Retained Earnings | (5.54 M) | |||
About Eastwood Bio Performance
Evaluating Eastwood Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Eastwood Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eastwood Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Eastwood Bio-Medical Canada Inc. researches and develops natural health products in North America and Asia. Eastwood Bio-Medical Canada Inc. is a subsidiary of Eastwood Bio-Medical Research Inc. EASTWOOD BIO operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.Things to note about Eastwood Bio Medical performance evaluation
Checking the ongoing alerts about Eastwood Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eastwood Bio Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eastwood Bio Medical generated a negative expected return over the last 90 days | |
| Eastwood Bio Medical has high historical volatility and very poor performance | |
| Eastwood Bio Medical has some characteristics of a very speculative penny stock | |
| Eastwood Bio Medical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 867.94 K. Net Loss for the year was (546.6 K) with profit before overhead, payroll, taxes, and interest of 407.05 K. | |
| Eastwood Bio Medical Canada has accumulated about 708.26 K in cash with (16.89 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 70.0% of the company shares are held by company insiders |
- Analyzing Eastwood Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eastwood Bio's stock is overvalued or undervalued compared to its peers.
- Examining Eastwood Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eastwood Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eastwood Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eastwood Bio's stock. These opinions can provide insight into Eastwood Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eastwood Stock Analysis
When running Eastwood Bio's price analysis, check to measure Eastwood Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eastwood Bio is operating at the current time. Most of Eastwood Bio's value examination focuses on studying past and present price action to predict the probability of Eastwood Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eastwood Bio's price. Additionally, you may evaluate how the addition of Eastwood Bio to your portfolios can decrease your overall portfolio volatility.